drugset / Trial / NCT02458287

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

NCT02458287 ↗

Phase 3 Completed 299 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).

Timeline

Start
2015-06
Primary completion
2016-02
Completion
2016-02

Outcome

Met primary endpoint

registry p <0.001; LS Mean Difference -63.4 (95% CI -72.0 to -54.7) NCT02458287 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bococizumab Monoclonal antibody 75 mg Subcutaneous
Subject Bococizumab Monoclonal antibody 150 mg Subcutaneous

Indications